Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

59459 1490631916HCLSReviewIrelandMarch2017.pdf
Energy Boardroom

Mystery investment fund eyes $640M bid for struggling obesity drug maker Vivus

29.05.2014 / Fierce Pharma

Vivus has been through a lot over the past year, including an all-out proxy war, a myriad of exec exits and, most recently, a generic threat from Actavis to its flailing obesity drug Qsymia. And now? It appears to have an interested buyer, according to a regulatory filing.

Cover_HCLS_Ireland LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: